Efficacy of treating acute cerebral infarction by Batroxobin combined with Aspirin
- VernacularTitle:巴曲酶联合抗血小板聚集药治疗急性脑梗死的疗效观察
- Author:
Maohong CAO
;
Kaifu KE
- Publication Type:Journal Article
- Keywords:
acute cerebral infarction;
Batroxobin;
Aspirin;
combined treatment
- From:
Journal of Clinical Neurology
1988;0(02):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect and safety of Batroxobin (DF-521) combined with Aspirin (ASA) in the treatment of acute cerebral infarction. Methods 102 patients with acute cerebral infarction were enrolled in the study and all the patients were divided into three groups: ASA group (n=23), Batroxobin group (n=35) and ASA combined with Batroxobin group (n=44). Platelet count, blood viscosity, platelet aggregation test (PAgT), fibrinogen, coagulation studies (PT, APTT, INR), TXB2, imaging, National Institutes of Health Stroke Scale (NIHSS) and Modified Barthel Index (MBI) were measured or assessed before and after treatment, respectively. Hemorrhage rate (including brain and other organs) as one of complication was also investigated.Results After treatments, ASA combined with Batroxobin group showed the strongest inhibition of platelet aggregation among the three groups (all P0.05). A follow up of 3 months showed that the scores of NIHSS and MBI in ASA combined with Batroxobin group were better than those in the other two groups (all P
